Literature DB >> 10781747

Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications.

J L Hsu1, S L Glaser.   

Abstract

Epstein-Barr virus (EBV), a ubiquitous B-lymphotrophic herpesvirus, has been found in the tumor cells of a heterogeneous group of malignancies (Burkitt's lymphoma, lymphomas associated with immunosuppression, other non-Hodgkin's lymphomas, Hodgkin's disease, nasopharyngeal carcinoma, gastric adenocarcinoma, lymphoepithelioma-like carcinomas, and immunodeficiency-related leiomyosarcoma). As the epidemiologic characteristics of these cancers have not been considered together, this review seeks to relate their incidence patterns and risk factors to EBV biology and virus-host interaction in an attempt to help elucidate factors involved in EBV-related carcinogenesis. We include a brief review of EBV virology and primary infection to provide a biologic context for considering the epidemiology, summarize the most salient epidemiologic features of each malignancy, synthesize epidemiologic data by risk factor to uncover commonalities and informative contrasts across the diseases, and propose hypotheses regarding etiologic mechanisms, based on the possible effect of the risk factors at various stages in the viral life cycle.

Entities:  

Mesh:

Year:  2000        PMID: 10781747     DOI: 10.1016/s1040-8428(00)00046-9

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  75 in total

Review 1.  Molecular pathways in virus-induced cytokine production.

Authors:  T H Mogensen; S R Paludan
Journal:  Microbiol Mol Biol Rev       Date:  2001-03       Impact factor: 11.056

2.  Epstein-Barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient.

Authors:  Andi Krumbholz; Tim Sandhaus; Angela Göhlert; Albert Heim; Roland Zell; Renate Egerer; Martin Breuer; Eberhard Straube; Peter Wutzler; Andreas Sauerbrei
Journal:  Med Microbiol Immunol       Date:  2010-07-20       Impact factor: 3.402

3.  A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma.

Authors:  Kimberly A Bertrand; Brenda M Birmann; Ellen T Chang; Donna Spiegelman; Jon C Aster; Shumin M Zhang; Francine Laden
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

Review 4.  Lessons from rare tumors: hepatic lymphoepithelioma-like carcinomas.

Authors:  Antonio Solinas; Diego F Calvisi
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

5.  A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.

Authors:  Susan P Perrine; Olivier Hermine; Trudy Small; Felipe Suarez; Richard O'Reilly; Farid Boulad; Joyce Fingeroth; Melissa Askin; Arthur Levy; Steven J Mentzer; Massimo Di Nicola; Alessandro M Gianni; Christoph Klein; Steven Horwitz; Douglas V Faller
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

Review 6.  Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

Authors:  Donald R Shaffer; Cliona M Rooney; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

7.  Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens.

Authors:  John Craddock; Helen E Heslop
Journal:  Update Cancer Ther       Date:  2008-03

8.  Transmembrane Domains Mediate Intra- and Extracellular Trafficking of Epstein-Barr Virus Latent Membrane Protein 1.

Authors:  Dingani Nkosi; Lauren A Howell; Mujeeb R Cheerathodi; Stephanie N Hurwitz; Deanna C Tremblay; Xia Liu; David G Meckes
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

9.  Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway.

Authors:  Pamela M Pegman; Sinéad M Smith; Brendan N D'Souza; Sinéad T Loughran; Sabine Maier; Bettina Kempkes; Paul A Cahill; Matthew J Simmons; Céline Gélinas; Dermot Walls
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

10.  Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.

Authors:  R Bultema; R Longnecker; M Swanson-Mungerson
Journal:  Oncogene       Date:  2009-02-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.